Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  McKesson Corporation    MCK

MCKESSON CORPORATION

(MCK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

McKesson : RETEVMO (selpercatinib), FDA-Approved for Treatment of RET-driven Lung and Thyroid Cancers, Available at Biologics by McKesson

share with twitter share with LinkedIn share with facebook
06/02/2020 | 10:11am EDT

CARY, N.C., June 2-Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Eli Lilly and Company as a specialty pharmacy provider for RETEVMOTM (selpercatinib), the first drug approved by the U.S. Food and Drug Administration (FDA) specifically for patients with advanced RET-driven non-small cell lung cancer (NSCLC) and thyroid cancers.

RETEVMO, approved by the FDA on May 8, 2020, is indicated for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as well as adults and children 12 years and older with either advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy or with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and are radioactive iodine-refractory (if radioactive iodine is appropriate). Crossing the blood-brain barrier, this drug shrinks tumors in parts of the central nervous system, including the brain. This is important to RET fusion-positive NSCLC patients because up to 50% can have tumors that metastasize to the brain.

'This is a critical new treatment option for patients with RET-driven lung and thyroid cancers because RETEVMO inhibits RET,' said Brandon Tom, vice president of Commercial Services with Biologics. 'We're proud to be able to work with Eli Lilly to help make this therapy available for patients to take at home.'

Biologics specialty pharmacy is committed to and recognized for its quality level of customer service as well as its innovative, high-touch and multidisciplinary patient-centric approach. Each team includes pharmacists with in-depth knowledge of therapies, experienced nurses, and financial counselors who are familiar with various financial assistance programs and organizations that help patients. This deeply-skilled care team works together to develop individualized care plans that address each patient's unique clinical, financial and emotional needs and streamlines communication back to the treating provider, enabling high-quality care and differentiated outcomes. In addition, the Biologics team works closely with payers to ensure patients can access the specialty medications they need.

Physicians may submit prescriptions to Biologics via phone (800.850.4306), fax (800.823.4506) or eScribe. For electronic prescribing systems, physicians may search for Biologics within their EMR system.

About Biologics by McKesson

Biologics by McKesson is an independent specialty pharmacy with more than 25 years of experience connecting patients to life-changing medications in oncology and other rare and complex therapeutic areas. Built on the foundation of deep clinical expertise and a high-touch approach to patient care, Biologics delivers seamless access and personalized engagement, so patients get the most out of the care they receive. As part of McKesson Life Sciences, a business within McKesson Corporation, Biologics harnesses unparalleled reach and connectivity across the healthcare system to connect the dots between payers, providers and biopharma, so together, they can deliver better care and outcomes for every patient.

PR Contact

Claire Crye
Public Relations
281-825-9927
Claire.Crye@McKesson.com



CARY, N.C., June 2-Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Eli Lilly and Company as a specialty pharmacy provider for RETEVMOTM (selpercatinib), the first drug approved by the U.S. Food and Drug Administration (FDA) specifically for patients with advanced RET-driven non-small cell lung cancer (NSCLC) and thyroid cancers.

RETEVMO, approved by the FDA on May 8, 2020, is indicated for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as well as adults and children 12 years and older with either advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy or with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and are radioactive iodine-refractory (if radioactive iodine is appropriate). Crossing the blood-brain barrier, this drug shrinks tumors in parts of the central nervous system, including the brain. This is important to RET fusion-positive NSCLC patients because up to 50% can have tumors that metastasize to the brain.

'This is a critical new treatment option for patients with RET-driven lung and thyroid cancers because RETEVMO inhibits RET,' said Brandon Tom, vice president of Commercial Services with Biologics. 'We're proud to be able to work with Eli Lilly to help make this therapy available for patients to take at home.'

Biologics specialty pharmacy is committed to and recognized for its quality level of customer service as well as its innovative, high-touch and multidisciplinary patient-centric approach. Each team includes pharmacists with in-depth knowledge of therapies, experienced nurses, and financial counselors who are familiar with various financial assistance programs and organizations that help patients. This deeply-skilled care team works together to develop individualized care plans that address each patient's unique clinical, financial and emotional needs and streamlines communication back to the treating provider, enabling high-quality care and differentiated outcomes. In addition, the Biologics team works closely with payers to ensure patients can access the specialty medications they need.

Physicians may submit prescriptions to Biologics via phone (800.850.4306), fax (800.823.4506) or eScribe. For electronic prescribing systems, physicians may search for Biologics within their EMR system.

About Biologics by McKesson

Biologics by McKesson is an independent specialty pharmacy with more than 25 years of experience connecting patients to life-changing medications in oncology and other rare and complex therapeutic areas. Built on the foundation of deep clinical expertise and a high-touch approach to patient care, Biologics delivers seamless access and personalized engagement, so patients get the most out of the care they receive. As part of McKesson Life Sciences, a business within McKesson Corporation, Biologics harnesses unparalleled reach and connectivity across the healthcare system to connect the dots between payers, providers and biopharma, so together, they can deliver better care and outcomes for every patient.

PR Contact

Claire Crye
Public Relations
281-825-9927
Claire.Crye@McKesson.com



Disclaimer

McKesson Corporation published this content on 02 June 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 02 June 2020 14:10:08 UTC

share with twitter share with LinkedIn share with facebook
Latest news on MCKESSON CORPORATION
07/01MCKESSON : Changes Business-Unit Structure
DJ
07/01MCKESSON CORP : Regulation FD Disclosure, Financial Statements and Exhibits (for..
AQ
07/01MCKESSON : Realigns Organizational Structure to Better Serve Customers and Patie..
BU
06/30KARYOPHARM THERAPEUTICS : XPOVIO, FDA Approved for Treatment of Relapsed or Refr..
AQ
06/29MCKESSON : XPOVIO (selinexor), FDA Approved for Treatment of Relapsed or Refract..
PU
06/19MCKESSON : Partners with Walmart to Deliver nearly 10 million Critical Medical G..
PU
06/05MCKESSON : Appoints Tom Rodgers to Executive Vice President and Chief Strategy a..
AQ
06/04MCKESSON : Appoints Tom Rodgers to Executive Vice President & Chief Strategy and..
BU
06/03ELI LILLY AND : RETEVMO, FDA-Approved for Treatment of RET-driven Lung and Thyro..
AQ
06/02MCKESSON : RETEVMO (selpercatinib), FDA-Approved for Treatment of RET-driven Lun..
PU
More news
Financials (USD)
Sales 2021 236 B - -
Net income 2021 1 870 M - -
Net Debt 2021 2 045 M - -
P/E ratio 2021 13,2x
Yield 2021 1,12%
Capitalization 24 760 M 24 760 M -
EV / Sales 2020
EV / Sales 2021 0,11x
Nbr of Employees 70 000
Free-Float 59,5%
Chart MCKESSON CORPORATION
Duration : Period :
McKesson Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MCKESSON CORPORATION
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 171,18 $
Last Close Price 152,73 $
Spread / Highest target 27,0%
Spread / Average Target 12,1%
Spread / Lowest Target -3,75%
EPS Revisions
Managers
NameTitle
Brian Scott Tyler Chief Executive Officer & Director
Edward A. Mueller Chairman
Britt Vitalone Chief Financial Officer & Executive Vice President
Nancy Flores EVP, Chief Technology & Information Officer
M. Christine Jacobs Independent Director
Sector and Competitors